PL2512236T3 - Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb) - Google Patents

Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb)

Info

Publication number
PL2512236T3
PL2512236T3 PL10838355T PL10838355T PL2512236T3 PL 2512236 T3 PL2512236 T3 PL 2512236T3 PL 10838355 T PL10838355 T PL 10838355T PL 10838355 T PL10838355 T PL 10838355T PL 2512236 T3 PL2512236 T3 PL 2512236T3
Authority
PL
Poland
Prior art keywords
beta
hmb
methylbutyrate
hydroxy
improved method
Prior art date
Application number
PL10838355T
Other languages
English (en)
Inventor
John Rathmacher
John Fuller
Shawn Baier
Steve Nissen
Naji Abumrad
Original Assignee
Metabolic Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Technologies, Inc. filed Critical Metabolic Technologies, Inc.
Publication of PL2512236T3 publication Critical patent/PL2512236T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10838355T 2009-12-18 2010-12-20 Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb) PL2512236T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28785709P 2009-12-18 2009-12-18

Publications (1)

Publication Number Publication Date
PL2512236T3 true PL2512236T3 (pl) 2017-06-30

Family

ID=44167737

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10838355T PL2512236T3 (pl) 2009-12-18 2010-12-20 Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb)

Country Status (11)

Country Link
US (1) US20120053240A1 (pl)
EP (1) EP2512236B1 (pl)
JP (2) JP6077857B2 (pl)
CN (1) CN102762097B (pl)
CA (1) CA2784836C (pl)
DK (1) DK2512236T3 (pl)
ES (1) ES2608483T3 (pl)
HU (1) HUE032486T2 (pl)
PL (1) PL2512236T3 (pl)
PT (1) PT2512236T (pl)
WO (1) WO2011075741A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014000419A (es) * 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
BR112015005199B1 (pt) * 2012-09-10 2022-09-06 Metabolic Technologies, Inc Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo
EP2993994A4 (en) * 2013-03-14 2016-11-23 Metabolic Technologies Inc LIQUIDS AND FOODS WITH BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) IN A FREE ACID FORM
WO2014152606A2 (en) 2013-03-14 2014-09-25 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
US20140272000A1 (en) * 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
CA2903561C (en) * 2013-03-15 2017-09-26 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
EP3082778B1 (en) * 2013-12-18 2019-04-03 Capsugel Belgium NV Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid
WO2015105981A2 (en) * 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
CN106536060A (zh) 2014-01-28 2017-03-22 卫理公会医院 包括单细胞移液器手柄和单细胞移液器尖端的单细胞移液器组件
JP6309287B2 (ja) * 2014-01-29 2018-04-11 協和発酵バイオ株式会社 3−ヒドロキシ−3−メチル酪酸カルシウム含有飲料
CN118844612A (zh) * 2014-03-14 2024-10-29 代谢科技有限公司 含有游离酸形式的β-羟基-β-甲基丁酸盐(HMB)的液体和食品
US20160184248A1 (en) * 2014-12-15 2016-06-30 University Of Central Florida Research Foundation Inc. Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
ES2937282T3 (es) * 2015-06-01 2023-03-27 Metabolic Tech Llc Composiciones y métodos de uso del beta-hidroxi-beta-metilbutirato (HMB) para disminuir la masa grasa
AU2016323779B2 (en) * 2015-09-16 2022-03-17 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
BR112018009406A8 (pt) 2015-11-10 2019-02-26 Metabolic Tech Inc ?composição de aditivo de ração, produto de ração, método para prevenir, eliminar e/ou reduzir crescimento microbiano, e, revestimento para um produto de ração animal?
AU2017207910B2 (en) * 2016-01-13 2022-09-01 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for joint stability
CN121695115A (zh) 2016-01-21 2026-03-20 代谢科技有限责任公司 β-羟基-β-甲基丁酸(HMB)用于调节自噬和噬脂的组合物和方法
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
RU2018145520A (ru) * 2016-05-25 2020-06-25 ТиЭсАй ГРУП ЛТД. Стабилизация композиций бета-гидроксиизовалериановых кислот в мягких гелевых капсулах
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
JP7583523B2 (ja) 2016-10-21 2024-11-14 メタボリック・テクノロジーズ,インコーポレーテッド β-ヒドロキシ-β-メチルブチレート(HMB)およびプロバイオティックを使用する組成物および方法
US12370159B2 (en) * 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
JP7022420B2 (ja) * 2017-06-30 2022-02-18 株式会社東洋新薬 経口組成物
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US20190209501A1 (en) * 2018-01-05 2019-07-11 Texas Tech University Office of Research Commercialization Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) assosiated with intermittent fasting
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10888576B2 (en) 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN121695118A (zh) * 2026-02-13 2026-03-20 中国科学技术大学 Hmb或含hmb物质在制备用于预防和/或减轻酒精宿醉和/或缓解急性酒精性肝损伤药物的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US20010008641A1 (en) * 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
JP4744081B2 (ja) * 2001-08-31 2011-08-10 ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー 植物抽出物を用いて障害を処置するための方法
DE10215007A1 (de) * 2002-04-05 2003-10-16 Degussa Bioactives Deutschland Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20080317886A1 (en) * 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
DK2381784T3 (en) * 2008-12-09 2018-10-22 Metabolic Tech Inc Nutritional intervention to improve muscle function and strength
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤

Also Published As

Publication number Publication date
PT2512236T (pt) 2016-12-29
EP2512236B1 (en) 2016-10-19
DK2512236T3 (en) 2017-01-16
CN102762097A (zh) 2012-10-31
JP6077857B2 (ja) 2017-02-08
US20120053240A1 (en) 2012-03-01
JP2016026181A (ja) 2016-02-12
JP2013515009A (ja) 2013-05-02
WO2011075741A1 (en) 2011-06-23
EP2512236A4 (en) 2013-06-19
EP2512236A1 (en) 2012-10-24
HUE032486T2 (en) 2018-05-02
CN102762097B (zh) 2015-06-17
ES2608483T3 (es) 2017-04-11
CA2784836A1 (en) 2011-06-23
CA2784836C (en) 2019-08-20

Similar Documents

Publication Publication Date Title
PT2512236T (pt) Método aperfeiçoado de administração de beta-hidroxi-beta-metilbutirato (hmb)
AP3155A (en) Methods of administering pirfenidone therapy
HUE055739T2 (hu) Eljárás terápiás alkalmazásra
GB201018147D0 (en) Method of treatment
SI2427477T1 (sl) Postopek priprave ciklopeptidov
IL216951A0 (en) Method for treatment of diseases
GB201003920D0 (en) Method of treatment
IL213955A (en) Method for improved biological activity of pharmaceutical preparations
GB0908101D0 (en) Treatment of stress
GB201018149D0 (en) Method of treatment
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2404891A4 (en) PROCESS FOR THE PREPARATION OF ACYL BENZENES
EP2585103A4 (en) METHOD OF TREATMENT
GB201020015D0 (en) Method of treatment
AP2984A (en) An arteether injection for treatment of malaria
GB0909807D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment
GB0920070D0 (en) Method of processing blood
GB201005071D0 (en) Method of treatment
GB201003917D0 (en) Method of treatment
GB201000318D0 (en) Method of treatment
GB201019936D0 (en) Therapeutic method
GB0915895D0 (en) Method of cleansing
AU2009903360A0 (en) Method of Treatment